Hangzhou TianMuShan Pharmaceutical EnterpriseLtd 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

What Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's (SHSE:600671) 27% Share Price Gain Is Not Telling You

Oct 25

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) Investors Are Less Pessimistic Than Expected

Jul 18

CEO

Hangzhou TianMuShan Pharmaceutical EnterpriseLtd 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Guojun Dang	Vice Chairman & Board Secretary	3.5yrs	CN¥110.10k	데이터 없음
Yang Pei	Independent Director	3.5yrs	CN¥100.00k	데이터 없음
Hua Cheng	Employee Supervisor	3yrs	데이터 없음	데이터 없음
Lu Wang	Supervisor	2.5yrs	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

38.5yo

평균 연령

경험이 풍부한 이사회: 600671 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.

Hangzhou TianMuShan Pharmaceutical EnterpriseLtd 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, Annual General Meeting, May 20, 2024

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New major risk - Financial position

What Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's (SHSE:600671) 27% Share Price Gain Is Not Telling You

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.072 loss per share (vs CN¥0.12 loss in 2Q 2023)

New minor risk - Market cap size

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) Investors Are Less Pessimistic Than Expected

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.074 loss in 1Q 2023)

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, Annual General Meeting, May 20, 2024

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

On October 19, 2023 Qingdao Yuanjia Medical Treatment Technology propose of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise.

New minor risk - Share price stability

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.13 loss in 2Q 2022)

First quarter 2023 earnings released: CN¥0.074 loss per share (vs CN¥0.048 loss in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.074 loss per share (vs CN¥0.074 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.13 loss per share (vs CN¥0.025 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.048 loss per share (vs CN¥0.025 loss in 1Q 2021)

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.074 loss per share (vs CN¥0.014 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.025 loss per share (vs CN¥0.02 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.33 loss per share (vs CN¥0.41 profit in FY 2019)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥8.56

Third quarter earnings released

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd to Report Q3, 2020 Results on Oct 31, 2020

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd to Report First Half, 2020 Results on Aug 31, 2020

CEO

이사회 구성원

평균 재임 기간

평균 연령